Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) ·
[[:Category:Basal_insulins|Basal insulin]] (2) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) ·
[[:Category:Insulins|Insulin]] (2) ·
[[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) ·
[[:Category:Long-acting_insulins|Long-acting insulin analog]] (2) ·
[[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1)
mechanism:
None (2) ·
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) ·
'"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1) ·
'"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1)
uses:
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)
starting dose:
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
20 mg PO twice daily, or 40 mg at bedtime (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
preparations:
1 mg, 2 mg, 4 mg tablets (1) ·
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
100 U/mL FlexTouch pen, vial (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1)
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)
bioavailability:
40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)
pregnancy:
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.